EA2183 - Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

NCT#:

NCT QR Code

Title:

Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

Protocol:

EA2183

Cancer Type:

Esophageal/Gastric

Study Sponsor:

NCI / ECOG-ACRIN

Brief Summary:

This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding radiotherapy to the usual chemotherapy may work better compared to the usual chemotherapy alone in treating patients with esophageal and gastric cancer.

Study Type:

Interventional

Date Opened at SVH:

2-Sep-2021

Recruitment Status:

Recruiting

Study Population:

Eligibility Criteria:

See Schema

Principal Investigator:

Hong Zhao, MD, Oncology, Salinas Valley Health Cancer Care, (831) 755-1701

Participating Institution: